GlaxoSmithKline, the UK's largest pharmaceutical group, and rival AstraZeneca, saw shares jump sharply - with the latter up 10% - as a series of deals in the sector boosted prices.
Glaxo saw shares jump 4.7% when markets opened after it agreed to sell one of its businesses to rival Novartis, in a deal which will see it return billions of pounds to shareholders. But it was rival AstraZeneca which really rocketed, shares jumping 9.7% initially, after reports US rival Pfizer - a much larger company - will bid £60bn for the group. Britain's second-largest drugs maker is expected to do all it can to withstand any approach. Glaxo's gains seem the more sustainable after the group - a favourite holding of many income funds in the UK - today announced it had sold its ...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes